BioNTech SE (BNTX) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Mainz, Germany. Der aktuelle CEO ist Ugur Sahin.
BNTX hat IPO-Datum 2019-10-10, 6,772 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $24.73B.
BioNTech SE is a biotechnology company headquartered in Mainz, Germany, that develops and commercializes immunotherapies targeting cancer and infectious diseases. The company's pipeline includes multiple therapeutic programs: personalized cancer vaccines (FixVac candidates), neoantigen-specific immunotherapies including Autogene cevumeran, mRNA intratumoral immunotherapies, chimeric antigen receptor T cell therapies, checkpoint immunomodulators, and monoclonal antibodies, with most candidates in clinical development stages. BioNTech also develops prophylactic vaccines for COVID-19 and influenza, along with therapies for rare diseases. The company maintains strategic collaborations with major pharmaceutical and biotechnology partners including Pfizer, Sanofi, Genentech, Regeneron, and others to advance its diverse clinical pipeline.
